Gender-Biased Nuclear Medicine

Radioiodine therapy is essentially contra-indicated in patients who are known to be pregnant. Radioiodine easily crosses the placenta and the foetal thyroid begins to accumulate iodine at about 10 weeks of gestational age. If radioiodine treatment of thyroid carcinoma is to be performed, it should be delayed until after delivery. If this is done, the physician should also be aware that radioiodine is excreted in breast milk and breast-feeding should be stopped completely after a therapeutic dose. If this is not done the infant may become permanently hypothyroid or be at high risk for subsequent thyroid cancer.This session will discuss about the health concern of women exposed to radiation therapy, especially during the months of pregnancy, topics of discussion will include Gender Biases in Diseases, Pregnancy and Harmful effects of Radiation, Women with Ischemic Heart Disease, Osteoporosis, Gynecologic and Breast Oncologic Imaging, Radiation dose concerns for pregnant and lactating patients.


Nuclear Medicine should be practiced as gender-based medicine in management of particular diseases, when it is applied as personalized interventions or targeted therapy

  • Gender Biases in Diseases
  • Pregnancy and Harmful Effects of Radiation
  • Women With Ischemic Heart Disease
  • Osteoporosis
  • Gynecologic and Breast Oncologic Imaging

Related Conference of Gender-Biased Nuclear Medicine

Aug 27-28, 2018

21st World Congress on Radiology & Cancer Research

Toronto, Ontario, Canada
26-27th September, 2018

20th World Congress on Radiology and Oncology

Chicago, Illinois, USA

Gender-Biased Nuclear Medicine Conference Speakers

Recommended Sessions

Related Journals

Are you interested in